AU2004205372B2 - Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors - Google Patents

Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors Download PDF

Info

Publication number
AU2004205372B2
AU2004205372B2 AU2004205372A AU2004205372A AU2004205372B2 AU 2004205372 B2 AU2004205372 B2 AU 2004205372B2 AU 2004205372 A AU2004205372 A AU 2004205372A AU 2004205372 A AU2004205372 A AU 2004205372A AU 2004205372 B2 AU2004205372 B2 AU 2004205372B2
Authority
AU
Australia
Prior art keywords
alkyl
independently
group
compound according
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004205372A
Other languages
English (en)
Other versions
AU2004205372A1 (en
Inventor
Rasma Bokaldere
Paul W. Finn
Vija Gailite
Aleksandrs Gutcaits
Ivars Kalvinsh
Einars Loza
Irena Olutnika
Ludmila Serpionova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget UK Ltd
Original Assignee
Topotarget UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget UK Ltd filed Critical Topotarget UK Ltd
Publication of AU2004205372A1 publication Critical patent/AU2004205372A1/en
Application granted granted Critical
Publication of AU2004205372B2 publication Critical patent/AU2004205372B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
AU2004205372A 2003-01-17 2004-01-19 Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors Ceased AU2004205372B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44061603P 2003-01-17 2003-01-17
US60/440,616 2003-01-17
PCT/GB2004/000147 WO2004065354A1 (en) 2003-01-17 2004-01-19 Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors

Publications (2)

Publication Number Publication Date
AU2004205372A1 AU2004205372A1 (en) 2004-08-05
AU2004205372B2 true AU2004205372B2 (en) 2011-02-24

Family

ID=32771842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004205372A Ceased AU2004205372B2 (en) 2003-01-17 2004-01-19 Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors

Country Status (6)

Country Link
US (1) US7465719B2 (enExample)
EP (1) EP1583736A1 (enExample)
JP (1) JP4612621B2 (enExample)
AU (1) AU2004205372B2 (enExample)
CA (1) CA2513246A1 (enExample)
WO (1) WO2004065354A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
PL208401B1 (pl) 2002-03-13 2011-04-29 Janssen Pharmaceutica Nv Pochodne piperazynylowe, piperydynylowe i morfolinylowe, sposób ich wytwarzania, kompozycja je zawierająca oraz ich zastosowanie
ES2306858T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
NZ534771A (en) 2002-03-13 2006-04-28 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006122926A1 (en) 2005-05-18 2006-11-23 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2623360C (en) 2005-10-27 2014-04-22 Janssen Pharmaceutica N.V. Squaric acid derivatives as inhibitors of histone deacetylase
KR100696139B1 (ko) * 2005-11-01 2007-03-20 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체 및그의 제조방법
AU2007206950B2 (en) 2006-01-19 2012-02-02 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
ES2327972T3 (es) 2006-01-19 2009-11-05 Janssen Pharmaceutica, N.V. Derivados de aminofenil como nuevos inhibidores de histona deacetilasa.
WO2007082876A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP5277171B2 (ja) 2006-11-03 2013-08-28 コリア リサーチ インスティテュート オブ ケミカル テクノロジーズ ヒストン脱アセチル化酵素阻害活性を有するナフタレニルオキシプロペニル誘導体およびこれを含む薬学組成物
JP2010513326A (ja) * 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
CN101646651A (zh) 2007-03-28 2010-02-10 参天制药株式会社 具有脲结构的新型吡啶羧酸（2-氨基苯基）酰胺衍生物
CA2680838A1 (en) * 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
AU2008338631A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
JP2011507909A (ja) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド 四置換ベンゼン
US8198271B2 (en) 2008-05-23 2012-06-12 Santen Pharmaceutical Co., Ltd. Thiophenediamine derivative having urea structure
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS532852B2 (enExample) 1972-04-25 1978-02-01
JPS5777646A (en) 1980-10-31 1982-05-15 Kanto Kagaku Kk Preparation of hydroxamic acid
JPH04217950A (ja) 1990-03-28 1992-08-07 Asahi Chem Ind Co Ltd ヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
JPH0775593A (ja) 1993-09-08 1995-03-20 Suntory Ltd 蛋白質の製造方法
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
JP2001500533A (ja) 1997-07-10 2001-01-16 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー マトリックスメタロプロテイナーゼ・インヒビター
DK1030836T3 (da) 1997-11-12 2003-05-26 Darwin Discovery Ltd Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
JP2002523492A (ja) 1998-08-29 2002-07-30 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド タンパク質分解酵素阻害剤としてのヒドロキサム酸誘導体
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
DE19858548A1 (de) 1998-12-18 2000-06-21 Schlafhorst & Co W Fadenführer zum traversierenden Zuführen eines Fadens zu einer rotierend angetriebenen Auflaufspule
JP2002536373A (ja) 1999-02-08 2002-10-29 ジー・ディー・サール・アンド・カンパニー スルファメトヒドロキサム酸メタロプロテアーゼ阻害剤
JP2003525203A (ja) 1999-03-22 2003-08-26 ダーウィン・ディスカバリー・リミテッド ヒドロキサムおよびカルボン酸誘導体
CA2366264A1 (en) * 1999-04-02 2000-10-12 Bristol-Myers Squibb Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
GB9911073D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
CA2373500A1 (en) 1999-05-12 2000-11-23 G.D. Searle & Co. Hydroxamic acid derivatives as matrix metalloprotease inhibitors
CA2379061C (en) 1999-08-10 2008-12-09 British Biotech Pharmaceuticals Limited Antibacterial agents
KR20070053362A (ko) 1999-11-23 2007-05-23 메틸진, 인크. 히스톤 디아세틸라제의 억제제
GB9929979D0 (en) 1999-12-17 2000-02-09 Darwin Discovery Ltd Hydroxamic acid derivatives
US20030139419A1 (en) 2000-02-21 2003-07-24 Bernard Barlaam Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
ATE489360T1 (de) * 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
JP2003533521A (ja) 2000-05-15 2003-11-11 ダーウィン・ディスカバリー・リミテッド ヒドロキサム酸誘導体
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002028829A2 (en) 2000-09-25 2002-04-11 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
NZ525439A (en) 2000-09-29 2004-11-26 Topotarget Uk Ltd Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US20050119305A1 (en) * 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors

Also Published As

Publication number Publication date
CA2513246A1 (en) 2004-08-05
US20060058282A1 (en) 2006-03-16
EP1583736A1 (en) 2005-10-12
AU2004205372A1 (en) 2004-08-05
JP4612621B2 (ja) 2011-01-12
US7465719B2 (en) 2008-12-16
JP2006517532A (ja) 2006-07-27
WO2004065354A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
AU2004205372B2 (en) Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
AU2004215624B2 (en) Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
AU2003229883B2 (en) Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
AU2001290131B2 (en) Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
EP1335898B1 (en) Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US6960685B2 (en) Carbamic acid compounds comprising an ether linkage as HDAC inhibitors
AU2001290131A1 (en) Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
NZ535065A (en) Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
CA2765409A1 (en) Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HYDROXAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired